Shanghai Pharmaceutical (02607): Shangyao Hefeng's lincomycin hydrochloride injection passed the generic drug consistency evaluation

Zhitong Finance App News, Shanghai Pharmaceutical (02607) announced that recently, Shanghai Hefeng Pharmaceutical Co., Ltd. (hereinafter referred to as “Shangyao Hefeng”) received the “Drug Supplement Application Approval Notice” (Notice Number: 2026B05944) issued by the State Drug Administration for lincomycin hydrochloride injections. The drug passed the generic drug consistency evaluation.

Lincomycin hydrochloride injection is suitable for severe infections caused by sensitive strains such as streptococci, pneumococci, and staphylococci, but only for patients who are allergic to penicillin or who are determined by a doctor not to use penicillin. In July 2025, Shangyao Hefeng submitted a supplementary application to the State Drug Administration for the consistent evaluation of the quality and efficacy of the generic drug and was accepted. As of the date of this announcement, the company has invested approximately RMB 1.97 million in research and development costs for the drug's consistency evaluation.

According to relevant national policies, drug varieties that have passed the consistency evaluation will receive greater support in fields such as medical insurance payments and procurement by medical institutions. Therefore, Shangyao Hefeng's lincomycin hydrochloride injection has passed the generic drug consistency evaluation, which is conducive to expanding the market share of this drug, enhancing market competitiveness, and at the same time accumulating valuable experience in carrying out generic drug consistency evaluation work for the company's subsequent products.